Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2022 16:30 ET | Source: Genenta Science

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor...
May 04, 2022 07:30 ET | Source: Genenta Science

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

No dose limiting toxicity observed in previous three dose level cohortsRepresents a 50% higher dose than highest prior levelUpdate of guidance for trial MILAN, Italy and NEW YORK, May 04, 2022 ...
May 02, 2022 16:30 ET | Source: Genenta Science

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

MILAN, Italy and NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
April 27, 2022 07:30 ET | Source: Genenta Science

Genenta Announces Nomination of Mark A. Sirgo as Chair

35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta...
April 20, 2022 07:30 ET | Source: Genenta Science

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

MILAN, Italy and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
March 09, 2022 07:46 ET | Source: Genenta Science

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

MILAN, Italy and NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
February 24, 2022 07:30 ET | Source: Genenta Science

Genenta to Participate at Upcoming Investor Conferences

MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
December 17, 2021 16:15 ET | Source: Genenta Science

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

MILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor...
December 14, 2021 22:36 ET | Source: Genenta Science

Genenta Announces Pricing of Upsized Initial Public Offering

MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
November 16, 2021 07:30 ET | Source: Genenta Science

Genenta To Present Updated Phase I/II Data At Upcoming Scientific Congresses SNO AND ASH

MILAN, Italy and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene...